Precigen (PGEN) Current Deferred Revenue (2012 - 2026)
Precigen (PGEN) posted quarterly Current Deferred Revenue of $410000.0 for Q1 2026, down 82.81% year-over-year from $2.4 million in Q1 2025, and down 20.7% quarter-over-quarter from $517000.0 in Q4 2025.
Precigen (PGEN) Current Deferred Revenue (2012 - 2026) Analysis & Trends
Precigen (PGEN) has reported Current Deferred Revenue for 15 consecutive years, with $410000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue fell 82.81% year-over-year to $410000.0; the TTM figure through Mar 2026 stood at $410000.0 (down 82.81% YoY), while the FY2025 annual figure was $517000.0, down 12.22% from the prior year.
- Current Deferred Revenue declined to $410000.0 in Q1 2026 per PGEN's latest filing, from $517000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $2.7 million in Q1 2022 and bottomed at $15000.0 in Q2 2023.
- Historically, Current Deferred Revenue has averaged $1.0 million across 5 years, with a median of $509000.0 in 2023.
- Annual changes were most pronounced in 2022 — Current Deferred Revenue plunged 99.9% — and 2024, when it surged 2420.0%.
- Precigen's Current Deferred Revenue stood at $25000.0 in 2022, then soared by 1936.0% to $509000.0 in 2023, then gained by 15.72% to $589000.0 in 2024, then fell by 12.22% to $517000.0 in 2025, then declined by 20.7% to $410000.0 in 2026.
- Business Quant data shows PGEN's Current Deferred Revenue at $410000.0 in Q1 2026, $517000.0 in Q4 2025, and $480000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Precigen | 2.18 Bn | 2.18 Bn | 52.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 284,000.00 |
| Mar 31, 2026 | 410,000.00 |
| Dec 31, 2025 | 517,000.00 |
| Sep 30, 2025 | 480,000.00 |
| Jun 30, 2025 | 2.23 Mn |
| Mar 31, 2025 | 2.39 Mn |
| Dec 31, 2024 | 589,000.00 |
| Sep 30, 2024 | 2.44 Mn |
| Jun 30, 2024 | 378,000.00 |
| Mar 31, 2024 | 407,000.00 |
| Dec 31, 2023 | 509,000.00 |
| Sep 30, 2023 | 509,000.00 |
| Jun 30, 2023 | 15,000.00 |
| Mar 31, 2023 | 1.83 Mn |
| Dec 31, 2022 | 25,000.00 |
| Sep 30, 2022 | 1.89 Mn |
| Jun 30, 2022 | 164,000.00 |
| Mar 31, 2022 | 2.67 Mn |
| Dec 31, 2021 | 24.51 Mn |
| Sep 30, 2021 | 26.72 Mn |